8 Antibiotic Classes and the Infections Each One Targets

3. Fluoroquinolone Antibiotics - DNA Replication Disruptors

Fluoroquinolones, including ciprofloxacin, levofloxacin, and moxifloxacin, represent a synthetic class of antibiotics that achieve bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes required for DNA replication and repair processes. These broad-spectrum agents demonstrate remarkable efficacy against both gram-positive and gram-negative bacteria, with particular strength against gram-negative pathogens such as Pseudomonas aeruginosa, making them invaluable for treating complicated urinary tract infections, hospital-acquired pneumonia, and intra-abdominal infections. The excellent tissue penetration and bioavailability of fluoroquinolones, combined with their ability to achieve therapeutic concentrations in difficult-to-reach sites such as bone, prostate tissue, and the central nervous system, make them preferred agents for treating osteomyelitis, prostatitis, and certain cases of bacterial meningitis. Respiratory fluoroquinolones like levofloxacin and moxifloxacin have enhanced activity against gram-positive organisms, including Streptococcus pneumoniae, making them effective monotherapy options for community-acquired pneumonia in patients with risk factors for drug-resistant pathogens. However, the use of fluoroquinolones has become increasingly restricted due to serious adverse effects, including tendon rupture, peripheral neuropathy, and central nervous system toxicity, as well as their propensity to select for resistant organisms, leading to recommendations for reserved use in situations where alternative antibiotics are ineffective or contraindicated.

4. Aminoglycoside Antibiotics - Ribosomal Targeting Powerhouses

Aminoglycosides, including gentamicin, tobramycin, and amikacin, function as bactericidal antibiotics by irreversibly binding to the 30S ribosomal subunit, causing misreading of mRNA and ultimately leading to bacterial cell death through disruption of protein synthesis. These antibiotics excel in treating serious gram-negative infections, particularly those caused by Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, making them essential components of combination therapy for severe hospital-acquired infections, ventilator-associated pneumonia, and complicated intra-abdominal infections. The synergistic effects observed when aminoglycosides are combined with beta-lactam antibiotics or vancomycin significantly enhance their therapeutic efficacy, particularly against enterococcal endocarditis and serious staphylococcal infections, where this combination can overcome intrinsic resistance mechanisms and achieve bactericidal activity. Despite their potent antimicrobial effects, aminoglycosides require careful monitoring due to their narrow therapeutic window and potential for serious adverse effects, including nephrotoxicity and ototoxicity, which necessitates therapeutic drug monitoring and dose adjustments based on renal function and serum drug levels. The unique pharmacokinetic properties of aminoglycosides, characterized by concentration-dependent killing and a post-antibiotic effect, support once-daily dosing regimens that may reduce toxicity while maintaining therapeutic efficacy, though their poor oral absorption limits their use to parenteral administration in most clinical situations.